Amlocim

Quick links to important sections

Amlocim

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlocim

What is Amlocim? Defining the Active Compound and Classification

Property Description
Active ingredient Amlodipine (as besilate)
Form Oral Tablet (most common)
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
Common use Managing hypertension and angina
Origin Synthetic

Amlocim is a synthetic, prescription-only medication primarily used to manage certain chronic cardiovascular conditions by easing pressure within the blood vessels. The defining and singularly active component is the substance amlodipine, often contained as the salt amlodipine besilate. Amlodipine is formally classified as a calcium channel blocker (CCB), belonging to the Dihydropyridine group.

This classification is a key functional identifier: it signifies that the compound’s core mechanism involves selectively modulating the transmembrane influx of calcium ions into the vascular smooth muscle cells, which is central to its therapeutic action as an antihypertensive agent. Amlodipine aids in the long-term relaxation of blood vessels. The medication is clinically recognized for its sustained efficacy in maintaining lowered blood pressure throughout a 24-hour period.


Composition, Form, and General Therapeutic Role

Amlocim is typically supplied as a single-ingredient product for oral administration, most commonly in the solid tablet dosage form. The final product consists of the active ingredient, amlodipine besilate, combined with solid excipients required for reliable formulation and consistent oral delivery.

The general therapeutic role of Amlocim is to reduce the resistance encountered by the heart when pumping blood. By initiating the relaxation of blood vessels (vasodilation), the drug effectively reduces the force required to circulate blood, thereby serving the general purpose of lowering elevated blood pressure and reducing the heart’s overall workload. The long-acting nature of amlodipine supports once-daily dosing for managing chronic conditions. This characteristic is a key differentiating factor, streamlining patient adherence for chronic conditions like persistent hypertension.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Amlocim?

Possible side effects and safety information

Official Regulatory Adverse Reactions

The safety characteristics of Amlocim (amlodipine) are categorized in regulatory documents based on the frequency and the specific body system affected. Adverse reactions are grouped into categories such as Very Common, Common, Uncommon, Rare, and Very Rare, reflecting the incidence rates reported in clinical studies.

The most frequently reported adverse reaction is peripheral edema (swelling), which is classified as Very Common. Other commonly reported effects include headache, dizziness, somnolence (sleepiness), palpitations, flushing, and fatigue. These effects are often reported more frequently at the start of treatment or during initial dose adjustment periods.

Adverse reactions are also classified by System-Organ Class (SOC), covering systems such as the Nervous system (e.g., tremor, hypoesthesia), Gastrointestinal system (e.g., nausea, abdominal pain, gingival hyperplasia), Vascular system (e.g., hypotension, vasculitis), and Cardiac system (e.g., arrhythmias).

Serious Safety Concerns and Restrictions

Official labeling documents identify specific, clinically significant adverse reactions, though they are classified as Rare or Very Rare. These include serious reactions such as myocardial infarction, angioedema, hepatitis, pancreatitis, and severe skin disorders like Toxic Epidermal Necrolysis.

The use of Amlocim is subject to safety restrictions (contraindications) documented in regulatory labels, including individuals with severe hypotension, cardiogenic shock, high-grade aortic stenosis, or haemodynamically unstable heart failure following a heart attack.

Population-Specific Safety Notes

Cautionary notes are provided for specific patient populations. Due to the drug's extensive liver metabolism, official documents advise caution and potentially lower initial dosing for patients with impaired hepatic function. Similarly, safety constraints exist for use in the older adult population and in patients with established heart failure.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Amlocim (amlodipine) can result in a significant, potentially life-threatening exaggeration of its intended effects, requiring immediate medical attention. The official regulatory profile emphasizes risks associated with severe cardiovascular compromise.

Domain Documented Overdose Presentation
Cardiovascular Signs Profound systemic hypotension due to excessive peripheral vasodilatation, with the possibility of reflex tachycardia (rapid heartbeats).
Severe Outcomes The overdose may lead to a clinical state of shock and fatal outcomes have been reported. Noncardiogenic pulmonary edema is a serious documented complication.

When to Seek Urgent Medical Help (Mandated Actions)

In the event of a suspected overdose, seek emergency medical attention immediately. Clinically significant and prolonged hypotension requires active cardiovascular support and continuous monitoring. You must contact emergency services or a poison control center for guidance.

Management and Monitoring

The regulatory information states that no specific antidote is known. Management relies on symptomatic and supportive treatment, including the use of vasopressors and judicious administration of fluids to stabilize blood pressure. Due to the drug’s long elimination half-life of 30 to 50 hours, extended clinical observation in a monitored setting is required for unstable patients.

Patients with hepatic impairment may require extra caution during management due to the prolonged half-life, which extends the duration of potential overdose effects.

Therapeutic Uses of Amlocim

What Amlocim Treats: Main Uses and Benefits


Understanding the Therapeutic Support

Amlocim is commonly used in situations involving certain distressing symptoms. It helps address symptom clusters that may become intense or disruptive and is applied across domains where additional symptomatic support is needed, relevant in conditions characterized by periods of heightened symptoms and recurrent or episodic manifestations.

This medicine is applied to help manage symptomatic discomfort related to systemic imbalance, and to provide supportive relief during episodes marked by temporary physiological imbalance. Amlocim supports patients by providing symptomatic relief that helps them cope more steadily, contributing to easing the overall symptom load.

“This medicine is relevant in contexts marked by increased discomfort or tension, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Support for Symptom Clusters

Amlocim is commonly used when short-term symptomatic assistance is needed during phases where symptoms related to physical discomfort intensify, assisting with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility profile for Amlocim (Amlodipine) is defined by regulatory authorities, establishing specific populations who may use the medicine and those who must not. Use is strictly contraindicated for individuals with a known hypersensitivity to Amlocim, to amlodipine, or to other dihydropyridine derivatives.

Contraindication also applies to patients experiencing severe hypotension or clinical states like shock (including cardiogenic shock). For Adults, use is generally established across all labeled indications.

Age-Related Eligibility Use is established for hypertension in children aged 6 years and older; however, the medicine is not established for use in children under 6 years of age.

Conditional Use Populations Use is conditional for several groups: Patients with hepatic impairment are required to start on a lower initial dose due to decreased clearance. Older adults should also begin treatment with the lowest available dose. During pregnancy and lactation, use is conditional and only recommended when the expected benefit is determined to outweigh the risk, as the drug is excreted in human milk and safety is not fully established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amlocim (Amlodipine) is metabolized by the enzyme CYP3A4, which is located in the liver. This metabolic pathway is the primary basis for its documented interactions with certain other medicines.

Drugs that Increase Amlocim Levels:

Medicines that inhibit the CYP3A4 enzyme can reduce Amlocim's breakdown, leading to increased plasma concentrations and potentially raising the risk of effects like low blood pressure or swelling. Strong or moderate CYP3A4 inhibitors (such as certain antifungal or antiretroviral medicines) may require a dose adjustment for Amlocim.

Impact on Other Medicines:

Amlocim can affect the levels of other co-administered drugs. Specifically, Amlocim increases the systemic exposure of the cholesterol-lowering medication Simvastatin. To reduce the risk of muscle-related toxicity (myopathy), the dose of Simvastatin should not exceed 20 mg daily when taken in combination with Amlocim.

Other Noteworthy Interactions:

  • CYP3A4 Inducers: Medicines that induce (speed up) the activity of CYP3A4 may decrease the plasma concentration of Amlocim, potentially lowering its effectiveness.
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Long-term use of NSAIDs may attenuate the blood pressure-lowering effect of Amlocim.

Mechanism of Action

Amlocim (Amlodipine) is a dihydropyridine calcium channel blocker that modulates specific physiological processes by targeting core mechanisms that regulate smooth muscle contraction. Its primary action involves binding to and blocking L-type voltage-gated calcium channels , which are critical biological targets in the membranes of vascular smooth muscle cells. This interaction inhibits the influx of extracellular calcium ions ( Ca^2+) into the cell, a necessary step for initiating smooth muscle contraction. The resulting reduction of intracellular calcium directly initiates a signaling sequence that reduces the smooth muscle contractile state. This action is applied to adjust activity within peripheral pathways and modifies the downstream effects of calcium-dependent contraction, leading to a measurable decrease in resistance within the arterial network. Amlocim also engages mechanisms within the coronary circulation, where it modulates the signaling patterns characteristic of smooth muscle hyperactivity, leading to physiological adjustments that alter the vascular tone of the coronary arteries, influencing localized perfusion dynamics without reference to therapeutic outcomes.

Dosage and Administration Information

Amlocim is administered orally, primarily utilizing the tablet dosage form. The dosing regimen is defined by a once daily schedule, and standard instructions suggest taking the medicine at the same time each day to ensure predictable administration. Amlocim may be taken with or without food.

For adults, the standard starting dose is 5 mg once daily, and the dose can be adjusted up to the maximum recommended daily dose of 10 mg. This adjustment, or titration, is a key procedure and should proceed gradually, typically over a period of 7 to 14 days.

Population-specific rules define the use of a lower 2.5 mg starting dose for older adults and those with hepatic impairment. For pediatric patients aged 6 to 17 years, the starting dose is also 2.5 mg, with a maximum daily dose of 5 mg. Regarding missed timing, it is generally advised to take the forgotten dose as soon as remembered, but to skip the dose if the next scheduled intake is imminent, and never to double the amount to compensate. These guidelines establish the standardized approach for using the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amlocim

The clinical evidence for Amlocim (amlodipine) is derived from extensive, large-scale Randomized Controlled Trials (RCTs) and systematic reviews, which form the basis for regulatory conclusions regarding its use.


Research Evidence for Managing High Blood Pressure

The research on Amlocim for high blood pressure was studied for a large number of clinical trials. These studies primarily tracked how blood pressure measurements changed over time and explored patterns related to the occurrence of major heart events, such as stroke and heart attack, when Amlocim-based treatment was used compared to other active treatments or placebo. Long-term studies contribute to the broader evidence landscape by monitoring the incidence of cardiovascular outcomes across different patient groups over several years. Evidence highlights what is known about its use in studies for chronic conditions.

Research Evidence for Managing Chronic Stable Angina

The clinical evaluation for chest pain relies on placebo-controlled and active-comparator trials focused on outcomes related to physical discomfort. These studies examined patient-reported outcomes such as the weekly frequency of angina episodes and the use of rescue medication. Findings report patterns of symptom evolution in the observed populations and describe patterns in the utilization of sublingual nitroglycerin during the study period.

Evidence in Specific Patient Populations and Research Gaps

Clinical research explored the use of Amlocim in several specific groups, including older adults and pediatric patients (ages 6 to 17) with hypertension. Studies describe patterns related to blood pressure changes in these groups. However, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes for the use of higher doses in the pediatric population. Furthermore, while the research on short-term symptom patterns exists for angina, the long-term prognostic outcomes in stable angina management are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Amlocim (FAQ)


Q: How quickly should someone expect Amlocim to start working?

Official product information indicates that Amlocim is a long-acting medicine. While maximum concentrations in the blood are generally reached 6–12 hours after a dose, the medicine is designed to achieve consistent levels in the body, known as steady-state, after approximately 7 to 8 days of continuous daily use. This timeframe describes the period necessary for the concentration in the blood to stabilize.


Q: Does Amlocim cause weight gain or weight loss?

Regulatory documents state that both weight gain and weight decrease have been reported as side effects in clinical trials, although these reports were not common. Patients who experience peripheral edema (swelling), a common side effect of Amlocim, may note corresponding changes in their weight.


Q: Can Amlocim be taken with general over-the-counter pain relievers?

The official documentation advises caution regarding long-term use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), as this may lessen the blood pressure-lowering effect of Amlocim. However, there are no known interactions specifically documented with other common over-the-counter pain relievers.


Q: Are there any specific vitamins or supplements that interact with Amlocim?

Studies and official information indicate that taking a multivitamin with minerals alongside Amlocim has been reported as a moderate interaction that may decrease the effects of the medicine.


Q: Is it safe to drink coffee or tea while taking Amlocim?

Official documents do not list common beverages like coffee or tea as a concern; however, it is noted that consuming grapefruit or grapefruit juice may increase the concentration of Amlocim in the body. This increase could potentially worsen side effects.


Q: Is Amlocim suitable for people with pre-existing kidney issues?

According to the official product information, the way the body handles Amlocim is not significantly affected by impaired kidney function. Patients with kidney issues may generally receive the usual initial dose. It is also noted that Amlodipine is not dialyzable.


Q: What should be done if an interaction with another drug is suspected?

Regulatory guidelines state that patients should inform their healthcare provider about all other medications, vitamins, and supplements they are currently using. These documents also note that patients should not stop using any medications without first consulting a healthcare professional.


Q: What is the general recommended length of time Amlocim is used?

Amlocim is prescribed for the long-term management of chronic cardiovascular conditions, such as high blood pressure. Authorities note that if blood pressure-lowering medicines are required, they are often taken indefinitely to support the ongoing management of the condition.


Q: If Amlocim is stopped, do the benefits go away immediately?

Official warnings note that if treatment is suddenly stopped, the blood pressure could potentially return to its previous elevated level. Additionally, sudden withdrawal of the medication might also be associated with an exacerbation of angina (chest pain).


Q: What are the signs of an allergic reaction to Amlocim?

Signs of a serious allergic reaction, such as a severe form called angioedema, may involve swelling of the face, lips, tongue, or throat. Other signs to be aware of include difficulty breathing, or the occurrence of a skin rash or hives.


Q: Are there any known interactions between Amlocim and alcohol?

Regulatory patient information states that Amlocim and alcohol may have additive effects in lowering blood pressure. This combination may increase the risk of certain effects, such as dizziness, lightheadedness, or feeling sleepy.


Q: What is the definition of a 'major interaction' involving Amlocim?

Regulatory documents categorize interactions by their underlying mechanism (e.g., how they affect the CYP3A4 enzyme) and the need for dose changes. A 'major' interaction is typically considered by clinicians as one where the risk is considered highly significant and the combination is generally avoided.


Q: Do lifestyle changes like diet and exercise impact Amlocim's effectiveness?

Official patient information notes that healthy lifestyle changes, such as regular exercise and eating a low-salt diet, can generally support heart health. These measures are often recommended alongside medication for the overall management of blood pressure.


Q: Can Amlocim be split or crushed before taking it?

The regulatory information describes the product as an oral tablet for administration and mentions an alternative liquid solution form. The label does not explicitly state that the standard tablets can be split or crushed by the patient.


Q: How long does Amlocim stay in the body after the last dose?

According to the official product information on pharmacokinetics, Amlodipine has a prolonged terminal elimination half-life of 30 to 50 hours in adults with normal liver function. This long half-life supports the once-daily dosing schedule.


Q: Why is a sudden stop of Amlocim not recommended?

The official warnings and precautions section states that the sudden cessation of the medication might be associated with an exacerbation of angina (chest pain). This potential effect is the reason sudden withdrawal is typically addressed in regulatory documents.


Q: Does Amlocim affect blood sugar levels?

Although effects on blood sugar are not listed as a primary side effect, a safety note in regulatory documents indicates that co-administration of Amlocim with certain other drugs may require adjustment of antidiabetic treatment.


Q: Does Amlocim interact with birth control pills?

Information from certain official health authorities indicates that amlodipine is not expected to affect the action of hormonal contraception (birth control pills). Therefore, its use is described as compatible with hormonal contraceptives.


Q: Does Amlocim interact with common herbal remedies like St. John's Wort?

Official drug interaction databases identify St. John's Wort as a known CYP3A4 inducer. Combining this herbal remedy with Amlocim may reduce the amount of Amlocim in the blood, potentially lowering its overall effectiveness.


Q: What is the meaning of the safety classification given to Amlocim?

The regulatory classification (e.g., Very Common, Common, Rare) reflects the incidence rates documented during clinical studies. These categories are provided to help categorize side effects by their documented frequency of occurrence in observed patient populations.


Q: Can Amlocim affect a person's mood or mental clarity?

Regulatory labels list adverse reactions related to the Psychiatric system, including anxiety, depression, and abnormal dreams. Effects related to mental clarity, such as somnolence (sleepiness) and other nervous system issues, are also noted.

How should Amlocim be stored and disposed of?

Official Storage and Disposal Requirements

The stability and safety of Amlocim (amlodipine) are maintained by following the storage and handling conditions documented in official regulatory labeling.

Requirement Condition
Temperature Store at Controlled Room Temperature (20°C to 25°C).
Protection Keep in the original container and protect from moisture; do not freeze.
Child Safety Must be kept out of the sight and reach of children.

Unused or expired amlodipine must be handled according to specific disposal protocols. This includes discarding the product in accordance with local regulations or through a drug take-back program. It is explicitly required that the medicine not be flushed down the toilet or disposed of in any wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlocim found in:

A-Z Index: